This course has concluded on May 28, 2022

CE InformationCourse Outline

    The Evolving Role of DOACs in the Management of Venous and Arterial Disease

    FACULTY

    Marianne Brodmann, MD
    Angiology
    Medical University Graz
    Graz, Austria

    Manesh R. Patel, MD
    Chief, Division of Cardiology
    Duke University
    Durham, North Carolina

    Constantino Peña, MD
    Medical Director, Vascular Imaging
    Interventional Radiology
    Miami Cardiac & Vascular Institute
    Miami, Florida

    Ido Weinberg, MD, RPVI
    Associate Professor of Medicine
    Harvard Medical School
    Medical Director, VASCORE
    Co-Medical Director, Anticoagulation Management Services
    Massachusetts General Hospital
    Boston, Massachusetts

    PROVIDER STATEMENT

    Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.

    For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

    INTENDED LEARNERS

    Interventional radiologists, vascular surgeons, interventional cardiologists, nurses, technicians and other clinicians involved in the treatment of CV disease.

    LEARNING OBJECTIVES

    After participating in this activity, learners should be better able to:

    • Describe the prevalence, risk factors, and consequences associated with venous and arterial disease
    • Compare the mechanisms of action and pharmacokinetics of traditional anticoagulant therapies and DOACs
    • Evaluate the most recent clinical data on the efficacy and safety of DOACs to assess their role in the management of VTE and PAD
    • Incorporate clinical evidence and current guidelines into care plans for the optimal management of VTE and PAD

    CLAIMING CREDIT

    To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

    Release Date: May 28, 2021 
    Expiration Date: May 28, 2022 
    Estimated Time to Complete: 1.00 hour

    There is no fee associated with this activity.

    COMMERCIAL SUPPORT

    NACCME would like to thank the following company who has supported "The Evolving Role of DOACs in the Management of Venous and Arterial Disease" through educational grants and/or in-kind support: Janssen Scientific Affairs, LLC.

    CONTINUING EDUCATION

     

    In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIANS

    NACCME designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSING

    This continuing nursing education activity awards 1.00 contact hour.

    Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hour. 

    NURSE PRACTITIONER

    American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

    PHYSICIAN ASSISTANTS

    NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

    INTERPROFESSIONAL

    This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

    VASCULAR & INTERVENTIONAL RADIOGRAPHERS

    The Evolving Role of DOACs in the Management of Venous and Arterial Disease taking place from May 28, 2021 to May 28, 2022 has been approved for 1.0 A+ ARRT CE credits by the Association for Vascular and Interventional Radiographers (AVIR). The AVIR is an ARRT Recognized Continuing Education Evaluating Mechanism, (RCEEM). Reference #: AVIR210431R

    USE OF PROPRIETARY NAMES

    This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

    UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

    This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

    DISCLAIMERS

    The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

    Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

    The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

    DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

    NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

    In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

    Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

    1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
    2. any investigational, off-label, or non-FDA approved content or discussion

    NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

    Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

    1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
    2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
    3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

    FACULTY

    The faculty has reported the following:

    Dr. Brodmann: Consultant — BD Bard, Philips, Medtronic, Biotronik, Cagent, Boston Scientific, Shockwave, Bayer Healthcare; Speakers' Bureau — BD Bard, Philips, Medtronic, Biotronik, Cagent, Boston Scientific, Shockwave, Bayer Healthcare
    Dr. Patel: Research Grants: Bayer, Janssen, Novartis, Heartflow, NHBLI; Advisory Board: Bayer, Janssen, Heartflow, Amgen
    Dr. Peña: Consultant – Philips Medical, Avanos, Cardinal (Cordis), Boston Scientific, Venture Med, Surmodics; Speakers’ Bureau - Abbott Medical, BD (Bard), Cook Medical, Sirtex, Penumbra, Shockwave; Major Stock Shareholder: Cagent Medical; Integrity Spine; Other Financial or Material Support - CEC: Micromedex and Intact Vascular
    Dr. Weinberg: Consultant – Magneto Thrombectomy Solutions

    CLINICAL REVIEWER

    Brian Schiro, MD
    Interventional Radiologist
    Miami Cardiac & Vascular Institute
    Miami, Florida

    Dr. Schiro: Grant/Research Support – Medtronic; Speakers’ Bureau – Penumbra, Medtronic 

    PLANNING COMMITTEE

    Susie Seaman, NP, MSN, CWOCN (nurse planner)
    Susie Seaman Wound Care Consulting
    San Diego, CA

    Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).

    NACCME planners and staff include Samantha Conforti, Randy Robbin, Greaton Sellers, MaryEllen Fama and Colleen Waters.

    No NACCME planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

    ADA STATEMENT

    North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

    PRIVACY POLICY

    NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

    Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

    GRIEVANCE POLICY

    Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.